JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diaz, R. M.
Right arrow Articles by Vile, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diaz, R. M.
Right arrow Articles by Vile, R. G.

 Previous Article  |  Next Article 

J Virol, January 1998, p. 789-795, Vol. 72, No. 1
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Exchange of Viral Promoter/Enhancer Elements with Heterologous Regulatory Sequences Generates Targeted Hybrid Long Terminal Repeat Vectors for Gene Therapy of Melanoma

R. M. Diaz,1 T. Eisen,2 I. R. Hart,1 and R. G. Vile3,*

Richard Dimbleby Department of Cancer Research/ICRF Laboratory, Rayne Institute, St. Thomas' Hospital, London SE1 7EH,1 Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 0TL,2 and ICRF Laboratory of Molecular Therapy, ICRF Oncology Unit, Hammersmith Hospital, London W12 0NN,3 United Kingdom

Received 13 May 1997/Accepted 24 September 1997

To generate transcriptionally targeted vectors, tissue-specific elements of the human tyrosinase promoter were exchanged with corresponding viral elements in the Moloney murine leukemia virus long terminal repeat (LTR). From these experiments, a vesicular stomatitis virus type G pseudotyped, hybrid LTR vector that contained three tyrosinase enhancer elements and gave high-level, tightly tissue-specific expression at high titers (3 × 107 CFU/ml) was constructed.

* Corresponding author. Mailing address: ICRF Laboratory of Molecular Therapy, ICRF Oncology Unit, Hammersmith Hospital, DuCane Rd., London, W12 0NN. Phone: 181 383 8584. Fax: 181 383 3258. E-mail: R.Vile{at}icrf.icnet.uk.




This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.